IL17A and cancer: Rorc is dysregulated in a multitude of cancers and is likely to participate in carcinogenesis through the modulation of IL-17, androgen receptors, and protein arginine N-methyltransferase 2 (Prmt2), leading to a ligand-dependent interaction and co-regulation of mechanisms associated with the development of inflammatory diseases, homeostasis, and circadian rhythm [54,55].